Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Receivables - Other: 2009-2019

Historic Receivables - Other for Cytokinetics (CYTK) over the last 8 years, with Jun 2019 value amounting to $575,000.

  • Cytokinetics' Receivables - Other fell 94.46% to $575,000 in Q2 2019 from the same period last year, while for Jun 2019 it was $575,000, marking a year-over-year decrease of 94.46%. This contributed to the annual value of $4.6 million for FY2018, which is 53.09% down from last year.
  • Per Cytokinetics' latest filing, its Receivables - Other stood at $575,000 for Q2 2019, which was down 76.74% from $2.5 million recorded in Q1 2019.
  • In the past 5 years, Cytokinetics' Receivables - Other ranged from a high of $67.0 million in Q3 2016 and a low of $4,000 during Q2 2015.
  • In the last 3 years, Cytokinetics' Receivables - Other had a median value of $5.2 million in 2018 and averaged $6.3 million.
  • In the last 5 years, Cytokinetics' Receivables - Other plummeted by 99.97% in 2015 and then spiked by 142,453.19% in 2016.
  • Quarterly analysis of 5 years shows Cytokinetics' Receivables - Other stood at $12,000 in 2015, then spiked by 100.00% to $24,000 in 2016, then skyrocketed by 40,350.00% to $9.7 million in 2017, then crashed by 53.09% to $4.6 million in 2018, then slumped by 94.46% to $575,000 in 2019.
  • Its Receivables - Other stands at $575,000 for Q2 2019, versus $2.5 million for Q1 2019 and $4.6 million for Q4 2018.